Drug shrinks tumors before surgery in promising cancer trial
NCT ID NCT05116085
Summary
This study tested whether giving the immunotherapy drug tislelizumab before surgery could help people with early-stage colorectal cancer that has specific genetic features (called MSI-H or dMMR). The goal was to see if the drug could shrink or even eliminate the tumor before it was surgically removed. Researchers measured how much cancer was left after the drug treatment and monitored patients for side effects and long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The Affiliated Hospital of Qingdao University Branch South
Qingdao, Shandong, 266000, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233004, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.